Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virol...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Turkish |
| Published: |
Galenos Yayinevi
2022-12-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | https://www.mjima.org/text.php?&id=356 |
| _version_ | 1797912397344669696 |
|---|---|
| author | Deniz GÖKENGİN Oğuzhan ACET |
| author_facet | Deniz GÖKENGİN Oğuzhan ACET |
| author_sort | Deniz GÖKENGİN |
| collection | DOAJ |
| description | Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virologic suppression could be achieved or maintained in patients with baseline or acquired M184V/I mutation, doubts exists about its use. This report presents a patient living with human immunodeficiency virus infection who had no resistance test results available, had heavy treatment experience, and maintained viral suppression following switching to DTG + 3TC dual therapy. |
| first_indexed | 2024-04-10T11:55:21Z |
| format | Article |
| id | doaj.art-e55b1c4eb5d64aeeb5083661565ff342 |
| institution | Directory Open Access Journal |
| issn | 2147-673X |
| language | Turkish |
| last_indexed | 2024-04-10T11:55:21Z |
| publishDate | 2022-12-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| spelling | doaj.art-e55b1c4eb5d64aeeb5083661565ff3422023-02-15T16:16:49ZturGalenos YayineviMediterranean Journal of Infection, Microbes and Antimicrobials2147-673X2022-12-0111110.4274/mjima.galenos.2022.2022.46Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus InfectionDeniz GÖKENGİN0https://orcid.org/0000-0003-0704-2302Oğuzhan ACET1https://orcid.org/0000-0002-3138-9421Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, TurkeyEge University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, TurkeyDolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virologic suppression could be achieved or maintained in patients with baseline or acquired M184V/I mutation, doubts exists about its use. This report presents a patient living with human immunodeficiency virus infection who had no resistance test results available, had heavy treatment experience, and maintained viral suppression following switching to DTG + 3TC dual therapy.https://www.mjima.org/text.php?&id=356dolutegravirlamivudinedual antiretroviral treatment |
| spellingShingle | Deniz GÖKENGİN Oğuzhan ACET Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection Mediterranean Journal of Infection, Microbes and Antimicrobials dolutegravir lamivudine dual antiretroviral treatment |
| title | Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection |
| title_full | Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection |
| title_fullStr | Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection |
| title_full_unstemmed | Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection |
| title_short | Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection |
| title_sort | switching to dolutegravir lamivudine in a highly treatment experienced patient living with human immunodeficiency virus infection |
| topic | dolutegravir lamivudine dual antiretroviral treatment |
| url | https://www.mjima.org/text.php?&id=356 |
| work_keys_str_mv | AT denizgokengin switchingtodolutegravirlamivudineinahighlytreatmentexperiencedpatientlivingwithhumanimmunodeficiencyvirusinfection AT oguzhanacet switchingtodolutegravirlamivudineinahighlytreatmentexperiencedpatientlivingwithhumanimmunodeficiencyvirusinfection |